Christopher Gibson
CIK: 0001856369
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (97 total)
- Jun 5, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct40K shares at avg. $3.62$145K - Jun 5, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Conversion(C)Direct40K shares- - Jun 3, 2026PACB
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Award(A)DirectStock Option (right to buy)
74.5K shares- - May 22, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Conversion(C)Direct40K shares- - May 22, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct40K shares at avg. $3.08$123K - May 15, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct22.8K shares at avg. $3.04$69K - May 7, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Gift(G)Direct20K shares- - May 7, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Conversion(C)Direct60K shares- - May 7, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct40K shares at avg. $3.37$135K - Apr 22, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct40K shares at avg. $3.61$144K - Apr 22, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Conversion(C)Direct40K shares- - Apr 8, 2026PACB
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Award(A)Direct57.5K shares- - Apr 7, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct40K shares at avg. $3.10$124K - Apr 7, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Conversion(C)Direct40K shares- - Mar 23, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Conversion(C)Direct40K shares- - Mar 23, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct40K shares at avg. $3.25$130K - Mar 9, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Gift(G)Direct20K shares- - Mar 9, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Conversion(C)Direct20K shares- - Mar 3, 2026PACB
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Award(A)Direct53.9K shares- - Feb 19, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct40K shares at avg. $3.46$138K - Feb 19, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Conversion(C)Direct40K shares- - Feb 17, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct27.3K shares at avg. $3.49$95K - Feb 6, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct30.3K shares- - Feb 6, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct10.4K shares at avg. $3.56$37K - Feb 4, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Conversion(C)Direct40K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 5, 2026 |  RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 40,000 | $3.62 | $144,800 | Direct |
| Jun 5, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Conversion(C) | 40,000 | - | $0 | Direct |
| Jun 3, 2026 |  PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | Award(A) Stock Option (right to buy) | 74,497 | - | - | Direct |
| May 22, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Conversion(C) | 40,000 | - | $0 | Direct |
| May 22, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 40,000 | $3.08 | $123,200 | Direct |
| May 15, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 22,821 | $3.04 | $69,376 | Direct |
| May 7, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Gift(G) | 20,000 | - | $0 | Direct |
| May 7, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Conversion(C) | 60,000 | - | $0 | Direct |
| May 7, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 40,000 | $3.37 | $134,800 | Direct |
| Apr 22, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 40,000 | $3.61 | $144,400 | Direct |
| Apr 22, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Conversion(C) | 40,000 | - | $0 | Direct |
| Apr 8, 2026 | PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | Award(A) | 57,473 | - | $0 | Direct |
| Apr 7, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 40,000 | $3.10 | $124,000 | Direct |
| Apr 7, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Conversion(C) | 40,000 | - | $0 | Direct |
| Mar 23, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Conversion(C) | 40,000 | - | $0 | Direct |
| Mar 23, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 40,000 | $3.25 | $130,000 | Direct |
| Mar 9, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Gift(G) | 20,000 | - | $0 | Direct |
| Mar 9, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Conversion(C) | 20,000 | - | $0 | Direct |
| Mar 3, 2026 | PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | Award(A) | 53,913 | - | $0 | Direct |
| Feb 19, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 40,000 | $3.46 | $138,400 | Direct |
| Feb 19, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Conversion(C) | 40,000 | - | $0 | Direct |
| Feb 17, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 27,265 | $3.49 | $95,155 | Direct |
| Feb 6, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 30,346 | - | $0 | Direct |
| Feb 6, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 10,364 | $3.56 | $36,896 | Direct |
| Feb 4, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Conversion(C) | 40,000 | - | $0 | Direct |
1-25 of 97 transactions
About Gibson Christopher
Gibson Christopher (SEC CIK 0001856369) files insider reports with the SEC as Director of RECURSION PHARMACEUTICALS, INC. (RXRX) and Director of PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB).
Signal8 holds 39 ownership filings by Gibson Christopher (1 Form 3, 38 Form 4), filed between Sep 6, 2024 and Jun 5, 2026. Those filings report 97 transactions, from Sep 4, 2024 to Jun 5, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Gibson Christopher's filings is in MENLO PARK, CA.
Recent filings by Gibson Christopher
- Jun 5, 2026: Open-market sale of RXRX shares (Form 4, code S).
- Jun 5, 2026: Conversion of RXRX shares (Form 4, code C).
- Jun 3, 2026: Grant or award of PACB derivative securities (Form 4, code A).
- May 22, 2026: Conversion of RXRX shares (Form 4, code C).
- May 22, 2026: Open-market sale of RXRX shares (Form 4, code S).
Other insiders filing for RECURSION PHARMACEUTICALS, INC. (RXRX)
- Borgeson Blake, Director
- HERSHBERG ROBERT, Director
- Dar Zavain, Director
- Li Dean Y, Director
- Taylor Ben R, Chief Financial Officer
- Khan Najat, CEO and President